Drug Profile
Research programme: diagnostic imaging agents - Molecular Insight Pharmaceuticals
Alternative Names: MIP 170D; MIP 170SLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Molecular Insight Pharmaceuticals
- Class Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in CNS-disorders(Diagnosis) in USA (IV, Injection)
- 22 Jan 2013 Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals
- 25 Mar 2008 Preclinical development is ongoing